Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377 ·Status: RECRUITING ·Phase: PHASE1

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

NCT01011998 ·Status: WITHDRAWN ·Phase: PHASE2

Nilotinib for First-line Newly Diagnosed CML-CP Patients

NCT03942094 ·Status: UNKNOWN ·Phase: PHASE3

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

NCT06649422 ·Status: NOT_YET_RECRUITING

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

NCT04155411 ·Status: UNKNOWN ·Phase: PHASE4

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

NCT00100997 ·Status: COMPLETED ·Phase: PHASE1

Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

NCT05988047 ·Status: COMPLETED

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01961765 ·Status: COMPLETED ·Phase: PHASE1

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

NCT04739826 ·Status: RECRUITING

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

NCT00219752 ·Status: COMPLETED ·Phase: PHASE2

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740 ·Status: COMPLETED ·Phase: PHASE2

Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients

NCT06651866 ·Status: RECRUITING ·Phase: PHASE1

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT05241106 ·Status: RECRUITING ·Phase: PHASE2

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

NCT04677439 ·Status: UNKNOWN ·Phase: PHASE4

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT02272777 ·Status: COMPLETED ·Phase: PHASE3

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

NCT06820268 ·Status: RECRUITING ·Phase: PHASE1

Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide

NCT06069024 ·Status: COMPLETED

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

NCT00703300 ·Status: COMPLETED ·Phase: PHASE1

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

NCT01699217 ·Status: COMPLETED

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT06497062 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487 ·Status: COMPLETED ·Phase: PHASE3

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00004258 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187 ·Status: RECRUITING ·Phase: PHASE3

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

NCT01254188 ·Status: COMPLETED ·Phase: PHASE3

Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

NCT01417767 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3